HALF-YEAR REPORT 2021

2 | Roche Half-Year Report 2021 Finance in Brief Pharmaceuticals Key interim results Sales CER growth % Core operating pro˜t margin % of sales Diagnostics Group –2.9 +0.8 +51.1 +3.4 +8.3 +1.3 ˜˚˜˛ ˚˛˚˛ ˜˚˜˛ ˚˛˚˛ ˜˚˜˛ ˚˛˚˛ 44.1 47.2 25.7 16.8 37.9 40.2-2 0 2 4 6 8 10 44 46 48 50 0 10 20 30 40 50 Six months ended 30 ... ................
................